SNF–CVAE: Computational method to predict drug–disease interactions using similarity network fusion and collective variational autoencoder

Drug repositioning is an emerging approach to identify novel therapeutic potentials for approved drugs and discover therapies for previously untreatable diseases. Drug repositioning has also attracted considerable attention in the pharmaceutical industry due to its time and cost efficiency in the dr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Knowledge-based systems Ročník 212; s. 106585
Hlavní autoři: Jarada, Tamer N., Rokne, Jon G., Alhajj, Reda
Médium: Journal Article
Jazyk:angličtina
Vydáno: Amsterdam Elsevier B.V 05.01.2021
Elsevier Science Ltd
Témata:
Accuracy
Alzheimer's disease
Arthritis
Biomedicine
Candidates
Case studies
Clinical research
Clinical trials
Computational drug repositioning
Cost analysis
Deep learning
Disease
Drug similarity measures
Drugs
Genes
Genomics
Identification methods
Information
Linear analysis
Machine learning
Measures
Motivation
Networks
Nonlinear analysis
Pharmaceutical industry
Pharmaceuticals
Public relations
Reliability
Rheumatoid arthritis
Robustness
Similarity
Similarity measures
Similarity network fusion
Therapy
Deep learning
Computational drug repositioning
Similarity network fusion
Drug similarity measures
Machine learning
ISSN:0950-7051, 1872-7409
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Drug repositioning is an emerging approach to identify novel therapeutic potentials for approved drugs and discover therapies for previously untreatable diseases. Drug repositioning has also attracted considerable attention in the pharmaceutical industry due to its time and cost efficiency in the drug development process compared to the traditional de novo drug discovery process. Recent advances in genomics, the tremendous growth of large-scale publicly available data, the availability of high-performance computing capabilities, along with the rise of machine learning, have further motivated the development of computational drug repositioning approaches. Investigating the relationship between different biomedical entities (e.g., drugs, diseases, genes) is one vital part of most recent studies in the drug repositioning field. Drug–disease interaction (R-DI) prediction is another main issue in drug repositioning research. Combining these relationships and interactions when introducing computational methods to identify novel drug–disease interactions with high accuracy is very challenging. In this study, we propose a robust approach, SNF–CVAE, for predicting novel drug–disease interactions using drug-related similarity information and known drug–disease interactions. SNF–CVAE integrates similarity measures, similarity selection, similarity network fusion (SNF), and collective variational autoencoder (CVAE) to conduct a non-linear analysis and improve the drug–disease interaction prediction accuracy. We evaluated the robustness of SNF–CVAE using different information models, drug similarity calculation measures, and drug similarity information. Moreover, we compared SNF–CVAE performance with four state-of-the-art machine learning models. SNF–CVAE achieved outstanding performance in stratified 5-fold cross-validation (Prec = 0.902, Rec = 0.883, F1 = 0.893, AUC-ROC = 0.958, and AUC-PR=0.970). Furthermore, we showed the efficiency of SNF–CVAE in predicting novel drug–disease interactions by validating the top-ranked interactions against pharmaceutical indications and clinical trial studies, which resulted in substantial pieces of evidence for almost all of RDIs predicted by our proposed model. To further demonstrate the reliability and robustness of SNF–CVAE, we conducted two case studies on the top predicted drug candidates for potentially treating Alzheimer’s disease and Juvenile rheumatoid arthritis, which were successfully validated against clinical trials and published studies. In conclusion, we strongly believe that computational drug repurposing research could significantly benefit from integrating similarity measures and deep learning models to predict novel drug–disease interactions in heterogeneous networks. •We propose a robust approach, SNF–CVAE, for predicting novel drug–disease interactions using drug-related similarity information and known drug–disease interactions.•We evaluated the robustness of SNF–CVAE using different information models, drug similarity calculation measures, and drug similarity information.•We compared SNF–CVAE performance with four state-of-the-art machine learning models. SNF–CVAE achieved outstanding performance in stratified 5-fold cross-validation.•We conducted two case studies on the top predicted drug candidates for potentially treating Alzheimer’s disease and Juvenile rheumatoid arthritis, which were successfully validated against clinical trials and published studies. In conclusion,•We strongly believe that computational drug repurposing research could significantly benefit from integrating similarity measures and deep learning models to predict novel drug–disease interactions in heterogeneous networks.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0950-7051
1872-7409
DOI:10.1016/j.knosys.2020.106585